New Whitepaper: Automated Patch Clamp in Cystic Fibrosis Drug Discovery
In October 2020, Enterprise Therapeutics’ TMEM16A programme was acquired by Roche/Genentech. This acquisition was the culmination of a research and discovery journey initiated in 2014, with the goal of providing a novel treatment paradigm suitable for patients with cystic fibrosis and other muco-obstructive diseases.
In this new whitepaper, we describe how APC was instrumental in the success of Enterprise Therapeutics’ TMEM16A programme or as Martin Gosling (CEO) describes it “Automated
electrophysiology has been KEY not only in finding the chemistry start points but in supporting the programme through its entire lead optimization”.